First Sofosbuvir WHO Prequalification To Widen Access But How Far?
Executive Summary
WHO’s prequalification of the first sofosbuvir from Gilead licensee Mylan is expected to expand access to the HCV treatment, but much will depend on donor funding priorities, say experts. Gilead hopes direct negotiations with payers in certain territories can move the access needle further.
You may also be interested in...
Gilead Raises HCV Guidance Slightly, Still Mum On M&A
Gilead thinks 2017 HCV sales could reach as high as $9bn, still down from 2016, but higher than projected six months ago. Meanwhile, sales of TAF-based HIV regimens continue to grow and gain market share.
Natco gets approval for first Sovaldi generic in India
Natco Pharma has received regulatory approval to launch generic sofosbuvir tablets 400mg in India –the first company to get such clearance in the country.
Cut price generics in sight as Gilead licenses Sovaldi
Sovaldi (sofosbuvir) licensee Cipla intends to keep a ''very keen eye'' on the product's affordability and hopes, going forward, to pare prices below Gilead Sciences' reported $900 offer in Egypt for a course of treatment with the product.